Stock MURA MURAL ONCOLOGY PLC
Add to a list
To use this feature you must be a member
Log inSign up

Company Mural Oncology plc

Equities

MURA

IE000LK2BOB4

Biotechnology & Medical Research

Real-time Estimate Cboe BZX
Other stock markets
 20:22:42 14/05/2024 BST 		5-day change 1st Jan Change
3.825 USD +2.00% Intraday chart for Mural Oncology plc -0.26% -35.47%
04-04 Morgan Stanley Initiates Coverage on Mural Oncology With Overweight Rating, $13 Price Target MT
01-08 Mural Oncology plc Announces Enhancements to Late-Stage Clinical Trials CI

Business Summary

Mural Oncology plc is a clinical-stage oncology company. The Company is leveraging its protein engineering platform to develop cytokine-based immunotherapies for the treatment of cancer. It leverages its expertise in cytokine biology, immune cell modulation and protein engineering capabilities to develop immunotherapies. The Company is developing a portfolio of programs to broaden the potential and reach of cytokine-based immunotherapies for the treatment of cancers, particularly those with limited treatment options available. Its portfolio of programs includes Nemvaleukin alfa (Nemvaleukin)-IL-2, IL-12, and IL-18. Nemvaleukin is an engineered interleukin-2 (IL-2) variant designed to harness the potent anti-cancer capabilities of high-dose rhIL-2 while minimizing toxicity by selectively activating cancer-fighting CD8 T cells and NK cells. The tumor-targeted split IL-12 program focuses on delivering the therapeutic potential of IL-12 by splitting it into inactive component.

Number of employees: 117

Members of the board

Members of the board TitleAgeSince

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 16,922,550 16,520,219 ( 97.62 %) 0 97.62 %

Shareholders

NameEquities%Valuation
Armistice Capital LLC
9.798 %
1,658,000 9.798 % 6 M $
Westfield Capital Management Co. LP
9.150 %
1,548,418 9.150 % 5 M $
Westfield Capital Management Co. LP
7.803 %
1,320,547 7.803 % 5 M $
BlackRock Advisors LLC
6.170 %
1,044,198 6.170 % 4 M $
DUMAC, Inc.
5.932 %
1,003,763 5.932 % 4 M $
Vanguard Fiduciary Trust Co.
5.646 %
955,506 5.646 % 3 M $
Alta Fundamental Advisers LLC
3.546 %
600,000 3.546 % 2 M $
Newtyn Management LLC
2.630 %
445,000 2.630 % 2 M $
Prosight Management LP
2.473 %
418,505 2.473 % 1 M $
STATE STREET CORPORATION
2.231 %
377,586 2.231 % 1 M $
NameEquities%Valuation
Cafico Trust Co. Ltd.
100.00 %
25,000 100.00 % 88 250 $

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Bio Therapeutic Drugs

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
3.75 USD
Average target price
13 USD
Spread / Average Target
+246.67%
Consensus

Chiffre d''affaires - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
MURAL ONCOLOGY PLC Stock Mural Oncology plc
-35.47% 63.46M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+4.81% 111B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+12.13% 105B
BIONTECH SE Stock BioNTech SE
-12.55% 22.34B
ARGENX SE Stock argenx SE
-3.70% 21.93B
GENMAB A/S Stock Genmab A/S
-6.03% 18.59B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-35.21% 18.12B
BEIGENE, LTD. Stock BeiGene, Ltd.
-10.59% 16.96B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+4.17% 13.7B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+37.03% 12.45B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. MURA Stock
  4. Company Mural Oncology plc